Salute to cutting-edge research: EKFS awards Publication Prizes 2024

Bad Homburg v. d. Höhe, July 3, 2024 – Today the foundation Else Kröner-Fresenius-Stiftung (EKFS) is announcing the prizewinners of its Publication Prizes for this year. The distinction is honoring five research scientists for their outstanding and, from a medical viewpoint, highly relevant findings, which they published in 2023 and achieved within the scope of funding by EKFS.

Immunometabolism in asthma

The prevalence of allergies including allergic asthma is increasing in western civilizations and there is an unmet clinical need of novel treatment strategies. It has recently been shown that asthmatic lung inflammation is especially mediated by Th17 cells in therapy-resistant patients. The aim of this project is to investigate how the energy metabolism regulates the epigenome and gene expression, and, thereby, the T cell effector function of Th2 and Th17 cells during asthmatic airway inflammation.

STAT3-controlled cross-dressing of dendritic cells in anti-tumor immunity

One promising approach in the fight against cancer is to activate the immune system to detect and fight tumor cells. However, cancer cells have evolved many ways of protecting themselves from the immune system: For example, they hide within the tumor stroma or surround themselves with a cloud of inhibitory signals that inhibits the activity of infiltrating immune cells. In this project, we want to uncover the complex relationship between changes in the tumor stroma and the presentation of antigens on the surface of tumor cells in models of colorectal cancer.

Expression levels of T-bet and Eomes govern the exhaustion state of type 1 T cells in glioblastoma and contribute to the efficacy of dendritic cell vaccination therapy

Dendritic cell vaccination (DCV) induces an anti-tumor immune response in gliobastoma patients, but efficacy seems limited. Effector T cells expressing IFNγ and T-bet can be detected in the brains of vaccinated patients, suggesting successful stimulation of tumor-specific type 1 T cells. However, these cells simultaneously express high levels of Eomes, leading to upregulation of the immune checkpoint receptor PD-1, associated with T-cell dysfunction. Thus, there appears to be a rational to combine DCV with immune checkpoint blockade (ICB) to increase therapeutic efficacy.